Integrating molecular profiling, histological type and other variables

Defining the fingerprint of responsiveness to treatment

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The landscape of prognostication and prediction of responsiveness to systemic therapy for breast cancer patients has been recently enriched by the development of molecular assays, which enable to explore the whole universe of gene expression in the tumour cells and to unveil new prognostic and predictive markers. These molecular markers might well be used in combination with the established ones to address the many open questions that still pave the way to a truly personalized treatment. The actual clinical utility of the molecular assays is being tested in randomized clinical trials that require an unprecedented coordination of the activity of clinical investigators, pathologists and translational researchers worldwide.

Original languageEnglish
JournalBreast
Volume18
Issue numberSUPPL.3
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Dermatoglyphics
Research Personnel
Randomized Controlled Trials
Breast Neoplasms
Gene Expression
Therapeutics
Neoplasms
Pathologists

Keywords

  • Breast carcinoma
  • Gene expression profiling
  • Immunohistochemistry
  • Predictive markers
  • Prognostic markers

ASJC Scopus subject areas

  • Surgery

Cite this

@article{d11b8fca185e403d8fce50f037f07791,
title = "Integrating molecular profiling, histological type and other variables: Defining the fingerprint of responsiveness to treatment",
abstract = "The landscape of prognostication and prediction of responsiveness to systemic therapy for breast cancer patients has been recently enriched by the development of molecular assays, which enable to explore the whole universe of gene expression in the tumour cells and to unveil new prognostic and predictive markers. These molecular markers might well be used in combination with the established ones to address the many open questions that still pave the way to a truly personalized treatment. The actual clinical utility of the molecular assays is being tested in randomized clinical trials that require an unprecedented coordination of the activity of clinical investigators, pathologists and translational researchers worldwide.",
keywords = "Breast carcinoma, Gene expression profiling, Immunohistochemistry, Predictive markers, Prognostic markers",
author = "Giuseppe Viale",
year = "2009",
month = "10",
doi = "10.1016/S0960-9776(09)70269-3",
language = "English",
volume = "18",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "SUPPL.3",

}

TY - JOUR

T1 - Integrating molecular profiling, histological type and other variables

T2 - Defining the fingerprint of responsiveness to treatment

AU - Viale, Giuseppe

PY - 2009/10

Y1 - 2009/10

N2 - The landscape of prognostication and prediction of responsiveness to systemic therapy for breast cancer patients has been recently enriched by the development of molecular assays, which enable to explore the whole universe of gene expression in the tumour cells and to unveil new prognostic and predictive markers. These molecular markers might well be used in combination with the established ones to address the many open questions that still pave the way to a truly personalized treatment. The actual clinical utility of the molecular assays is being tested in randomized clinical trials that require an unprecedented coordination of the activity of clinical investigators, pathologists and translational researchers worldwide.

AB - The landscape of prognostication and prediction of responsiveness to systemic therapy for breast cancer patients has been recently enriched by the development of molecular assays, which enable to explore the whole universe of gene expression in the tumour cells and to unveil new prognostic and predictive markers. These molecular markers might well be used in combination with the established ones to address the many open questions that still pave the way to a truly personalized treatment. The actual clinical utility of the molecular assays is being tested in randomized clinical trials that require an unprecedented coordination of the activity of clinical investigators, pathologists and translational researchers worldwide.

KW - Breast carcinoma

KW - Gene expression profiling

KW - Immunohistochemistry

KW - Predictive markers

KW - Prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=71849094765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849094765&partnerID=8YFLogxK

U2 - 10.1016/S0960-9776(09)70269-3

DO - 10.1016/S0960-9776(09)70269-3

M3 - Article

VL - 18

JO - Breast

JF - Breast

SN - 0960-9776

IS - SUPPL.3

ER -